EUVIMEDEUVIMED entdecken
Crossref

Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow‐Up Study

Christy Riggott iD, Keeley M Fairbrass iD, Elspeth A Guthrie, Christopher J Black iD, Christian P Selinger, Alexander C Ford iD, David J Gracie

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Christy Riggott und 6 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK. Hauptthemen laut MEDLINE: Anxiety, Depression, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Poor psychological health affects many patients with inflammatory bowel disease (IBD), but the persistence of these symptoms is unclear.

Methods

We performed a longitudinal follow‐up study of patients whose anxiety and depression trajectories were established by symptom data collected at 3‐monthly intervals over the course of 1 year. We collected further anxiety and depression symptom data at yearly intervals over 2 years to determine the persistence of these symptoms in patients with IBD. Disease outcomes (flare/need for glucocorticosteroids, escalation of medical therapy, hospitalisation, or intestinal resection) were recorded to determine the effect of mood trajectories on the natural history of IBD.

Results

Of 770 patients with established anxiety trajectories, 486 (63.1%) provided further anxiety symptom data at 12 months, and 358 (45.5%) at 24 months. Of the 777 patients with established depression trajectories, 491 (63.2%) provided further depression symptom data at 12 months, and 362 (45.6%) at 24 months. Participants with symptoms of anxiety at 24 months were more likely to have a fluctuating, or persistently abnormal or worsening, anxiety trajectory during the first year ( p < 0.001 for trend). Participants with symptoms of depression at 24 months were more likely to have a fluctuating, or persistently abnormal or worsening, depression trajectory during the first year ( p < 0.001 for trend). Adverse disease outcomes were no more likely according to anxiety or depression trajectories.

Discussion

Poor psychological health persists for a substantial number of patients with IBD. Further work is needed to establish the long‐term effect of mood trajectories on disease outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnxietyDepressionInflammatory Bowel DiseasesHumansFemaleMaleAdultFollow-Up StudiesLongitudinal StudiesMiddle AgedYoung Adult

Stichwörter der Autor:innen

inflammatory bowel diseasemood trajectoriespsychological health

Autor:innen und Institutionen

  • Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
  • Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
  • Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.

ORCID-Profile: Christy Riggott, Keeley M Fairbrass, Christopher J Black, Alexander C Ford

Zitieren

APA

Riggott, C., Fairbrass, K. M., Guthrie, E. A., Black, C. J., Selinger, C. P., Ford, A. C., & Gracie, D. J. (2026). Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow‐Up Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70431

Vancouver

Riggott C, Fairbrass KM, Guthrie EA, Black CJ, Selinger CP, Ford AC, et al. Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow‐Up Study. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70431

BibTeX
@article{Riggott2026,
  author = {Riggott, Christy and Fairbrass, Keeley M and Guthrie, Elspeth A and Black, Christopher J and Selinger, Christian P and Ford, Alexander C and Gracie, David J},
  title = {Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow‐Up Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70431}
}
Kostenlos starten →